Figure 2 shows the reduction of externally added cytochrome c in the presence or absence of xanthomegnin. Addition of NADH produced an increase in the absorbance at 550 nm suggesting that the externally added cytochrome c was reduced by NADH-cytochrome c reductase of mitochondrial outer membranes (curve b). In the presence of xanthomegnin, cytochrome c was reduced at a higher rate than that in the control experiment (curve a). This suggests that the redox response of xanthomegnin increased the reduction rate of cytochrome c.

The reduction of cytochrome c by reduced xanthomegnin has already been demonstrated by us using ascorbateloaded liposomes 18. These data suggest that xanthomegnin, reduced by NADH-cytochrome c reductase present in the outer membranes was oxidized by cytochrome c. Cytochrome c, localized on the cytoplasmic-side of the mitochondrial inner membranes, may be reduced by xanthomegnin in a similar fashion as described above. This may give rise to a xanthomegnin-bypass as presented in figure 3.

As demonstrated in our previous communication¹⁹, xanthomegnin was also reduced by mitochondria respiring succinate or L-glutamate as a substrate. But the reduction was initiated when the dissolved oxygen of reaction mixture was completely consumed. The reduction was completely inhibited by antimycin A or cyanide. This evidence indicates that xanthomegnin can form a bypass only in the presence of NADH. Thus xanthomegnin may oxidize cytoplasmic NADH by means of mitochondrial electron transport system.

- Present address: Bioenergetic Laboratory, State University of New York at Albany, N.Y. 12222, U.S.A.
- Y. Ito, K. Kawai and Y. Nozawa, J. Biochem. 74, 805 (1973).
- J.G. Wirth, T.E. Beesley and S.A. Anand, Phytochemistry 4, 505 (1965)
- F. Blank, W.C. Day and G. Just, J. invest. Derm. 40, 133 (1963)
- F. Blank, A.S. Ng and G. Just, Can. J. Chem. 44, 2873 (1966).
- R.C. Durley, J. MacMillan, T.J. Simpson, A.T. Glen and
- W.B. Turner, J. chem. Soc., Perkins I, 163 (1975).

 M.E. Stack, R.M. Eppley, P.A. Dreifuss and A.E. Pohland,
 Appl. environm. Microbiol. 33, 351 (1977).

 T. Akita, K. Kawai, H. Shimonaka, Y. Nozawa, Y. Ito,
- S. Nishibe and Y. Ogihara, Jap. J. Med. Mycol. 16, 177 (1975).
- K. Kawai, T. Akita, S. Nishibe, Y. Nozawa, Y. Ogihara and Y. Ito, J. Biochem. 79, 145 (1976).
- W.W. Calton, M.E. Stack and R.M. Eppley; Toxic. appl. Pharmac. 38, 455 (1976).
- Y. Nozawa, Y. Hiraguri and Y. Ito, Mycopath. Mycol. appl. 41, 293 (1970).

- 11 A.F. Brodie, in: Biochemistry of Quinone, p.355. Academic Press, London and New York 1965.
- K. Kawai, T. Akita, R. Watanabe and Y. Nozawa, Jap. J. med. Mycol. 19, 24 (1978).
- O.H. Lowry, N.J. Rosebrough, A.L. Farr and R.J. Randall; J. biol. Chem. 193, 265 (1951).
- 14 G.L. Sottocasa, B. Kuylenstierna, L. Ernster and A. Bergstrand, J. Cell Biol. 32, 415 (1967).
- L. Ernster and B. Kuylenstierna, in: Mitochondria Structure and Function, p.5. Academic Press, London and New York 1969.
- 16 J.L. Purvis and J.M. Lowenstein, J. biol. Chem. 236, 2794 (1961).
- G. von Jagow and M. Klingenberg, Eur. J. Biochem. 12, 583 (1970).
- K. Kawai, T. Akita and Y. Nozawa, Experientia 34, 977 (1978).
- K. Kawai, T. Akita and H. Shimonaka, Med. Biol. 96, 61 (1978).

The inability of nuclear dehydrogenating clostridia to oxidize bile salt hydroxyl groups¹

I.A. Macdonald and M.J. Hill

Department of Medicine, Dalhousie University Halifax (Nova Scotia, Canada B3H 1W2), and Bacterial Metabolism Research Laboratory Colindale Hospital, London NW9 5DX (England), 5 September 1978

Summary. In a survey of the intracellular bile salt oxidoreductase activity in fecal bacteria, 16 strains of nuclear dehydrogenating clostridia and 2 strains of non-nuclear dehydrogenating C. paraputrificum were demonstrated unable to oxidize cholate at any of the 3 OH groups. Since nuclear dehydrogenation at the Δ -1 and Δ -4 position requires a 3-oxo precursor steroid, it appears that these organisms require the presence of a 3a-hydroxysteroid dehydrogenating organism for nuclear dehydrogenation.

In the intestinal flora, the primary bacteria capable of introducing double bonds into the steroid skeleton are the lecethinase negative clostridia: predominantly C. paraputrificum, C. indolis, and C. tertium². These organisms contain nuclear dehydrogenases (NDH) active at the Δ -1 and Δ -4 positions of the A ring of 3 oxo-bile salts and 3 oxosteroids^{3,4}. High fecal populations of nuclear dehydrogenating clostridia (NDC) and high fecal concentrations of bile salts have been associated with bowel cancer patients and may be thereby implicated in the aetiology of colon cancer. Putative aromatisation of bile salts and steroids by gut bacteria has been a proposed mechanism of carcinogen formation in the human bowel.

The requirement of NDC for 3 oxo-bile salts or 3 oxosteroids for the introduction of unsaturations into the A ring has prompted a search in these organisms for intracellular 3a-hydroxysteroid dehydrogenase (HSDH) activity which could then provide substrates for the NDH.

Methods and materials. Nuclear dehydrogenating and nonnuclear dehydrogenating clostridia were isolated from clinical sources⁵ and prescreened for the presence of NDH as demonstrated by the formation of $\Delta 1$ and $\Delta 4$ unsaturations into 5β -androstan-3, 17 dione and 3 oxo- 5β -cholanoate as described before³. These organisms were maintained in cooked meat medium at 4°C and grown in 10 ml Brain Heart Infusion medium containing 0.1% sodium thioglycolate and 1.0×10^{-3} M sodium cholate for 48 h.

Cultures were centrifuged at 6000×g for 20 min at 4°C in an International B-20 centrifuge. The pellet was resuspended in 1.5 ml of 0.1 M sodium phosphate containing 10⁻³ M

Degradation of primary bile salt by 3a-HSDH containing organisms and NDC, a proposed in vivo pathway.

EDTA and the bacteria were ruptured in a French Pressure Cell. The cell-free preparation was centrifuged at 6000×g for 20 min at 4 °C and the supernatant fluid was decanted from the pellet.

The cell-free preparation was assayed for 3a, 7a, and 12a-HSDH activity using as substrates: chenodeoxycholate, deoxycholate, taurolithocholate, and 3a-hydroxy-5a-androstan-17-one and cofactors: NAD and NADP (8 substrate-cofactors combinations). The formation of reduced nucleotide was followed at 25 °C at 340 mm using a Beckman spectrophotometer with a 25 cm Beckman recorder. Each assay cuvette contains 17×10^{-3} M NAD(P)+, 0.17 M glycine/NaOH buffer (pH 9.5), 10⁻³ M dihydroxy-substrate or 10⁻³ M monohydroxy-substrate and 100 µl of freshly prepared cell-free preparation. The spent bacterial medium containing undegraded cholate and putative metabolites was adjusted to pH 3.5 and extracted with an equal volume of diethyl ether. The extract was blown to dryness (N₂), reconstituted in 1/10 volume methanol/water, 4/1 (v/v) and plated (10 µl) onto thin layer silica plates. Samples were chromatographed in either form/methanol/acetic acid 40/4/2 (v/v/v) or in benzene/dioxane/acetic acid 70/20/2 (v/v/v). Plates were sprayed with either anisaldehyde⁶ or p-hydroxybenzaldehyde⁷, heated with heat gun and inspected in day light and under the UV lamp.

Results and discussion. None of the above described clostridia contained any demonstrable 3a, 7a, or 12a-hydroxysteroid dehydrogenase activities in the presence of cell-free preparations and NAD or NADP. None of the above organisms significantly metabolized sodium cholate on inspection of TLC plates although trace amounts of methyl cholate were evident in many of the organisms. A notable absence of 7a, 12a-dihydroxy-3 oxo- 5β -cholanoate was evident in all strains. No products visible under the UV lamp were detectable. This was expected in the absence of a suitable hydrogen acceptor such as menadione.

The presence of NDH yet apparent absence of HSDH in this group of organisms suggest a dependence of NDC on the presence of 3a-HSDH containing organisms in the gut (e.g. C. perfringens⁸ or E. lentum⁹). The presence of NADdependent 3a-HSDH active against sodium taurolithocholate or 3a-hydroxy-5a-androstan-17-one appears present in the vast majority of mixed fecal cultures in one study 10.

Moreover, C. perfringens (most strains of which contain 3a-HSDH) is a commonly carried organism 11.

The absence of HSDH in 16 NDC does not, however, preclude the possibility that other strains of NDC do exist which also contain 3a-HSDH. It does, however, allow the authors to propose a bile salt degradative pathway involving 2 or more organisms (figure). The fate of unsaturated bile salts in the human intestine remains unknown. Aromatized bile salts have not been, to the authors' knowledge, found in either stool or bile of the human, although aromatized products of cholesterol metabolism by the gut flora have been demonstrated in guinea-pig urine 12. The reversion to saturated primary bile salts in a steady-state fashion is more likely and is in keeping with the instability of 2,2',4,4' tritiated bile salts in the presence of human colonic flora¹³. The possibility of potentially carcinogenic epoxide formation¹⁴ in the human gut, although yet undemonstrated, remains an alternative which could explain the apparent association of NDC with bowel cancer⁵.

- This work is supported by the National Cancer Institute of Canada (IAM) and by the Cancer Research Campaign (MJH).
- B. S. Drasar and M. J. Hill, in: Human Intestinal Flora, p. 134. Academic Press, London, New York, San Francisco 1974.
- V.C. Aries, P. Goddard and M.J. Hill, Biochim. biophys. Acta *248*, 482 (1971)
- P. Goddard and M.J. Hill, Biochim. biophys. Acta 280, 336
- M.J. Hill, B.S. Drasar, R.E.O. Williams, T.W. Meade, A.G. Cox and J. E. P. Simpson, Lancet 1, 535 (1975)
- D. Kritchevsky, D.S. Martak and G.H. Rothblat, Analyt. Biochem. 5, 388 (1963).
- I.A. Macdonald, J. Chromat. 136, 348 (1977).
- I.A. Macdonald, C.E. Meier, D.E. Mahony and G.A. Costain, Biochim. biophys. Acta 450, 142 (1976).
- I.A. Macdonald, D.E. Mahony, J.F. Jellett and C.E. Meier, Biochim. biophys. Acta 489, 466 (1977).
- I.A. Macdonald, G.R. Webb and D.E. Mahony, Am. J. clin. Nutr. 31, 233 (1978).
- J.G. Collee, in: The Normal Microbial Flora of Man, p.205. Ed. F.A. Skinner and J.G. Carr. Academic Press, London, New York, San Francisco 1974.
- P. Goddard and M.J. Hill, J. Steroid Biochem, 5, 569 (1974). N.F. LaRusso, N.E. Hoffman and A.F. Hofmann, J. Lab. clin. Med. 84, 759 (1974).
- B. Kadis, J. Steroid Biochem. 9, 75 (1978).